Search Results for: CTNNB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
UBE2S ubiquitin conjugating enzyme E2 S
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Synthesis of active ubiquitin: roles of E1 and E2 enzymes
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
CDC27 cell division cycle 27
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
KAT2A lysine acetyltransferase 2A
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Ub-specific processing proteases
  • RNA Polymerase I Transcription Initiation
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Coenzyme A
SMAD2 SMAD family member 2
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Dexfosfoserine
  • Colorectal cancer
SMAD4 SMAD family member 4
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Colorectal cancer
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
  • Juvenile polyposis syndrome
APC APC regulator of WNT signaling pathway
  • Apoptotic cleavage of cellular proteins
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Deactivation of the beta-catenin transactivating complex
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants are not K63 polyubiquitinated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ovarian tumor domain proteases
  • Familial adenomatous polyposis
  • Esophageal cancer
  • Gastric cancer
  • Cancer of the anal canal
  • Gallbladder cancer
CCND1 cyclin D1
  • SCF(Skp2)-mediated degradation of p27/p21
  • Pre-NOTCH Transcription and Translation
  • RMTs methylate histone arginines
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional Regulation by VENTX
  • Transcriptional regulation by RUNX2
  • Regulation of RUNX1 Expression and Activity
  • RUNX3 regulates WNT signaling
  • RUNX3 regulates p14-ARF
  • Estrogen-dependent gene expression
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Acetylsalicylic acid
  • Arsenic trioxide
  • Encorafenib
  • Bryostatin 1
  • Hairy-cell leukemia
  • von Hippel-Lindau syndrome
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Laryngeal cancer
  • Breast cancer
CSNK1A1 casein kinase 1 alpha 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Activation of SMO
  • Activation of SMO
  • Fostamatinib
ERBIN erbb2 interacting protein
  • Signaling by ERBB2
  • Downregulation of ERBB2 signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
CASP3 caspase 3
  • Activation of caspases through apoptosome-mediated cleavage
  • SMAC (DIABLO) binds to IAPs
  • SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
  • Apoptotic cleavage of cellular proteins
  • SMAC, XIAP-regulated apoptotic response
  • Apoptosis induced DNA fragmentation
  • Degradation of the extracellular matrix
  • Signaling by Hippo
  • NADE modulates death signalling
  • Stimulation of the cell death response by PAK-2p34
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Apoptotic cleavage of cell adhesion proteins
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Other interleukin signaling
  • Pamidronic acid
  • Acetylsalicylic acid
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • Emricasan
  • Incadronic acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
  • Glycyrrhizic acid
ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinylestradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Stanolone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Elacestrant
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Polyestradiol phosphate
  • Norethynodrel
  • Octocrylene
  • Homosalate
  • Enzacamene
  • Zeranol
  • Ractopamine
  • Gestrinone
  • Propyl Gallate
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Estriol tripropionate
  • Fluoroestradiol F-18
FOXO1 forkhead box O1
  • AKT phosphorylates targets in the nucleus
  • Regulation of gene expression in beta cells
  • AKT-mediated inactivation of FOXO1A
  • Constitutive Signaling by AKT1 E17K in Cancer
  • MAPK6/MAPK4 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of localization of FOXO transcription factors
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Alveolar rhabdomyosarcoma
MAPK8 mitogen-activated protein kinase 8
  • Activation of BIM and translocation to mitochondria
  • Activation of BMF and translocation to mitochondria
  • NRAGE signals death through JNK
  • NRAGE signals death through JNK
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Activation of the AP-1 family of transcription factors
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-38 signaling
  • WNT5:FZD7-mediated leishmania damping
  • Tamoxifen
  • Minocycline
  • Pyrazolanthrone
  • 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
  • 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
  • N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
  • 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
  • 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
  • Halicin
PSEN1 presenilin 1
  • Nuclear signaling by ERBB4
  • Degradation of the extracellular matrix
  • Regulated proteolysis of p75NTR
  • NRIF signals cell death from the nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • EPH-ephrin mediated repulsion of cells
  • Neutrophil degranulation
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Noncanonical activation of NOTCH3
  • Acne inversa; Hidradenitis supprativa
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Alzheimer's disease (AD)
AMER1 APC membrane recruitment protein 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Osteopathia striata with cranial sclerosis
CARM1 coactivator associated arginine methyltransferase 1
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Estrogen-dependent gene expression
GRIN1 glutamate ionotropic receptor NMDA type subunit 1
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic acid
  • Tramadol
  • Enflurane
  • Atomoxetine
  • Pentobarbital
  • Methadone
  • Secobarbital
  • Meperidine
  • Acamprosate
  • Donepezil
  • Guaifenesin
  • Memantine
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Aripiprazole
  • Prasterone
  • 5,7-Dichlorokynurenic acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Esketamine
  • Fluciclovine (18F)
DVL1 dishevelled segment polarity protein 1
  • TCF dependent signaling in response to WNT
  • WNT mediated activation of DVL
  • PCP/CE pathway
  • PCP/CE pathway
  • Degradation of DVL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Negative regulation of TCF-dependent signaling by DVL-interacting proteins
  • RHO GTPases Activate Formins
  • WNT5:FZD7-mediated leishmania damping
  • WNT5:FZD7-mediated leishmania damping
DVL3 dishevelled segment polarity protein 3
  • TCF dependent signaling in response to WNT
  • WNT mediated activation of DVL
  • PCP/CE pathway
  • PCP/CE pathway
  • Degradation of DVL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Negative regulation of TCF-dependent signaling by DVL-interacting proteins
  • RHO GTPases Activate Formins
  • WNT5:FZD7-mediated leishmania damping
  • WNT5:FZD7-mediated leishmania damping
FOXO4 forkhead box O4
  • AKT phosphorylates targets in the nucleus
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of localization of FOXO transcription factors
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Regulation of FOXO transcriptional activity by acetylation
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes

Page 3 out of 10 pages